
SOPH Stock Forecast & Price Target
SOPH Analyst Ratings
Bulls say
Sophia Genetics is well positioned because its cloud-based, sequencer-agnostic SaaS platform monetizes the analysis layer, not the test, generating recurring usage fees while hospitals retain reimbursement risk and deepen adoption through in-house testing. Its moat compounds through a globally diverse network of roughly 1,000 institutions across 75 countries and more than 2.5 million genomic profiles, which improves algorithm performance, supports high retention, and expands use cases in clinical care and biopharma. Financially, 2025 revenue reached $77.3M, 2026 guidance is $92M–$94M, adjusted gross margin was 74.2% in 2025 and 75.4% in 1Q26, and the company targets adjusted EBITDA profitability in 2H27.
Bears say
Sophia Genetics is challenged by weak commercial execution, as 2024 revenue rose only 4% even while volumes increased 11%, implying a 6% to 7% decline in revenue per analysis and signaling softer monetization, partly from bioPharma headwinds. The bear case also assumes the BioPharma DDM segment stays near 5% of total revenue from 2026 to 2033, limiting peak revenue to $441M and leaving adjusted gross margins flat at about 70% without meaningful expansion. With the company still not profitable, facing intense competition, cybersecurity and IP risks, and potential dilution from continued equity financing, its path to durable earnings remains uncertain.
This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.
SOPH Analyst Forecast & Price Prediction
Start investing in SOPH
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Sophia Genetics SA (SOPH) Forecast
SOPH Analyst Forecast & Price Prediction
Start investing in SOPH
Order type
Buy in
Order amount
Est. shares
0 shares